Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia Corrigendum in /10.3892/or.2022.8463

Liang,Xinglin; Xia,Ruixiang

doi:10.3892/or.2021.8229

Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia

Corrigendum in: /10.3892/or.2022.8463

Authors:
- Xinglin Liang
- Ruixiang Xia
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: November 17, 2021 https://doi.org/10.3892/or.2021.8229
Article Number: 18
Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

KIF2A has been shown to be involved in the regulation of AML pathology, however, the mechanistic role of KIF2A in AML has not been fully identified. The present study aimed to identify the underlying mechanism of KIF2A regulation of AML cell function and chemosensitivity. A total of 58 patients with AML and 30 healthy subjects were enrolled for clinical analysis. AML cells (KG‑1 and Kasumi‑1) were transfected with KIF2A or control small interfering (si)RNA. PI3K/AKT pathway activator (740 Y‑P) and RhoA overexpression plasmid were added to rescue the effect of KIF2A siRNA. Cell proliferation, apoptosis, chemosensitivity to ADR and AraC, expression levels of mRNA/proteins associated with PI3K/AKT and RhoA/ROCK pathways were measured by Cell Counting Kit‑8, flow cytometry, reverse transcription‑quantitative PCR and western blotting. KIF2A was overexpressed, and correlated with higher levels of bone marrow blast, poor risk classification, lower treatment response and unfavorable survival profile in patients with AML. KIF2A siRNA inhibited proliferation but enhanced apoptosis and chemosensitivity to ADR and AraC in KG‑1 and Kasumi‑1 cells, which also inactivated PI3K/AKT and RhoA/ROCK pathways. Subsequent rescue experiments showed that 740 Y‑P and RhoA overexpression plasmid promoted cell survival and decreased chemosensitivity, which reversed the effect of KIF2A siRNA in KG‑1 and Kasumi‑1 cells. KIF2A was correlated with worse clinical features and survival in patients with AML; its knockdown promoted apoptosis and chemosensitivity by inactivating PI3K/AKT and RhoA/ROCK signaling pathways in AML cells. These data suggested KIF2A may be a potential prognostic marker and treatment target for AML management.

View Figures

View References

1	Kuykendall A, Duployez N, Boissel N, Lancet JE and Welch JS: Acute myeloid leukemia: The good, the bad, and the ugly. Am Soc Clin Oncol Educ Book. 38:555–573. 2018. View Article : Google Scholar : PubMed/NCBI
2	Jung J, Cho BS, Kim HJ, Han E, Jang W, Han K, Lee JW, Chung NG, Cho B, Kim M and Kim Y: Reclassification of acute myeloid leukemia according to the 2016 WHO classification. Ann Lab Med. 39:311–316. 2019. View Article : Google Scholar : PubMed/NCBI
3	National Cancer Institute: SEER Cancer stat facts: Acute myeloid leukemia (AML). https://seer.cancer.gov/statfacts/html/amyl.html/December 17–2018.
4	National Cancer Institute: SEER Cancer Statistics Review, 1975-2016. https://seer.cancer.gov/csr/1975_2016/April 18–2019
5	Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen CM, Yeguas A, Vidriales MB, González M, Saborido JR, Kraus S, et al: Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML). Blood. Jul 21–2021.(Epub ahead of print). doi: 10.1182/blood.2020009192. View Article : Google Scholar : PubMed/NCBI
6	Michelozzi IM, Kirtsios E and Giustacchini A: Driving CAR T stem cell targeting in acute myeloid leukemia: The roads to success. Cancers (Basel). 13:28162021. View Article : Google Scholar : PubMed/NCBI
7	Song MK, Park BB and Uhm JE: Targeted therapeutic approach based on understanding of aberrant molecular pathways leading to leukemic proliferation in patients with acute myeloid leukemia. Int J Mol Sci. 22:57892021. View Article : Google Scholar : PubMed/NCBI
8	Zhao M, Wang J, Qu M, Zhao Y, Wang H, Ke Y, Liu Y, Lei ZN, Liu HM, Hu Z, et al: OGP46 induces differentiation of acute myeloid leukemia cells via different optimal signaling pathways. Front Cell Dev Biol. 9:6529722021. View Article : Google Scholar : PubMed/NCBI
9	Lu W and Gelfand VI: Moonlighting motors: Kinesin, dynein, and cell polarity. Trends Cell Biol. 27:505–514. 2017. View Article : Google Scholar : PubMed/NCBI
10	Chen K, Nam W and Epureanu BI: Collective intracellular cargo transport by multiple kinesins on multiple microtubules. Phys Rev E. 101:0524132020. View Article : Google Scholar : PubMed/NCBI
11	Scherer J, Yi J and Vallee RB: Role of cytoplasmic dynein and kinesins in adenovirus transport. FEBS Lett. 594:1838–1847. 2020. View Article : Google Scholar : PubMed/NCBI
12	Ganem NJ and Compton DA: The KinI kinesin Kif2a is required for bipolar spindle assembly through a functional relationship with MCAK. J Cell Biol. 166:473–478. 2004. View Article : Google Scholar : PubMed/NCBI
13	Zhang Q, Lu D, Liu W, Ye S, Guo H, Liao T and Chen C: Effects of KIF2A on the prognosis of nasopharyngeal carcinoma and nasopharyngeal carcinoma cells. Oncol Lett. 18:2718–2723. 2019.PubMed/NCBI
14	Wang G, Wang Z and Yu H: Kinesin family member 2A high expression correlates with advanced tumor stages and worse prognosis in non-small cell lung cancer patients. J Clin Lab Anal. 34:e231352020.PubMed/NCBI
15	Ding T, Li J, Sun J, Fan X, Shi C, Zhou D and Deng R: Association of kinesin family member 2A with increased disease risk, deteriorative clinical characteristics, and shorter survival profiles in acute myeloid leukemia. Braz J Med Biol Res. 54:e91732020. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Zhang X, Wang Y, Liu X, Zhao A, Yang Z, Kong F, Sun L, Yu Y and Jiang L: KIF2A promotes the progression via AKT signaling pathway and is upregulated by transcription factor ETV4 in human gastric cancer. Biomed Pharmacother. 125:1098402020. View Article : Google Scholar : PubMed/NCBI
18	Li X, Shu K, Wang Z and Ding D: Prognostic significance of KIF2A and KIF20A expression in human cancer: A systematic review and meta-analysis. Medicine (Baltimore). 98:e180402019. View Article : Google Scholar : PubMed/NCBI
19	Li D, Sun H, Meng L and Li D: The Overexpression of kinesin superfamily protein 2A (KIF2A) was associated with the proliferation and prognosis of esophageal squamous cell carcinoma. Cancer Manag Res. 12:3731–3739. 2020. View Article : Google Scholar : PubMed/NCBI
20	Zhang S, Huang F, Wang Y, Song Q, Yang X and Wu H: KIF2A overexpression and its association with clinicopathologic characteristics and poor prognoses in patients with gastric cancer. Dis Markers. 2016:74845162016. View Article : Google Scholar : PubMed/NCBI
21	Wang ZX, Ren SC, Chang ZS and Ren J: Identification of kinesin family member 2A (KIF2A) as a promising therapeutic target for osteosarcoma. Biomed Res Int. 2020:71027572020.PubMed/NCBI
22	Zhao P, Lan F, Zhang H, Zeng G and Liu D: Down-regulation of KIF2A inhibits gastric cancer cell invasion via suppressing MT1-MMP. Clin Exp Pharmacol Physiol. 45:1010–1018. 2018. View Article : Google Scholar : PubMed/NCBI
23	Zhang X, Ma C, Wang Q, Liu J, Tian M, Yuan Y, Li X and Qu X: Role of KIF2A in the progression and metastasis of human glioma. Mol Med Rep. 13:1781–1787. 2016. View Article : Google Scholar : PubMed/NCBI
24	Xie T, Li X, Ye F, Lu C, Huang H, Wang F, Cao X and Zhong C: High KIF2A expression promotes proliferation, migration and predicts poor prognosis in lung adenocarcinoma. Biochem Biophys Res Commun. 497:65–72. 2018. View Article : Google Scholar : PubMed/NCBI
25	Darici S, Alkhaldi H, Horne G, Jørgensen HG, Marmiroli S and Huang X: Targeting PI3K/Akt/mTOR in AML: Rationale and clinical evidence. J Clin Med. 9:29342020. View Article : Google Scholar : PubMed/NCBI
26	Nepstad I, Hatfield KJ, Grønningsæter IS and Reikvam H: The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci. 21:29072020. View Article : Google Scholar : PubMed/NCBI
27	Li X, Su Y, Hege K, Madlambayan G, Edwards H, Knight T, Polin L, Kushner J, Dzinic SH, White K, et al: The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica. 106:1262–1277. 2021.PubMed/NCBI
28	Hao Y, Zhang N, Wei N, Yin H, Zhang Y, Xu H, Zhu C and Li D: Matrine induces apoptosis in acute myeloid leukemia cells by inhibiting the PI3K/Akt/mTOR signaling pathway. Oncol Lett. 18:2891–2896. 2019.PubMed/NCBI
29	Annageldiyev C, Tan SF, Thakur S, Dhanyamraju PK, Ramisetti SR, Bhadauria P, Schick J, Zeng Z, Sharma V, Dunton W, et al: The PI3K/AKT pathway inhibitor ISC-4 induces apoptosis and inhibits growth of leukemia in preclinical models of acute myeloid leukemia. Front Oncol. 10:3932020. View Article : Google Scholar : PubMed/NCBI
30	Xu Y, Li K, Wang SB and Yang SG: MiR-592 functions as a tumor suppressor in acute myeloid leukemia by targeting ROCK1 and predicts patients' prognosis. Eur Rev Med Pharmacol Sci. 23:1610–1619. 2019.PubMed/NCBI
31	Liu Y, Gao X and Tian X: High expression of long intergenic non-coding RNA LINC00662 contributes to malignant growth of acute myeloid leukemia cells by upregulating ROCK1 via sponging microRNA-340-5p. Eur J Pharmacol. 859:1725352019. View Article : Google Scholar : PubMed/NCBI
32	Wang K, Lin C, Wang C, Shao Q, Gao W, Song B, Wang L, Song X, Qu X and Wei F: Silencing Kif2a induces apoptosis in squamous cell carcinoma of the oral tongue through inhibition of the PI3K/Akt signaling pathway. Mol Med Rep. 9:273–278. 2014. View Article : Google Scholar : PubMed/NCBI